HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hecht, J. R. Search for Related Content PubMed PubMed Citation Articles by Hecht, J. R. Social Bookmarking                         What's this?

J. RANDOLPH HECHT, M.D., is Professor of Clinical Medicine and Director, University of California Los Angeles (UCLA) Gastrointestinal Oncology Program, David Geffen School of Medicine at UCLA, 10945 Le Conte Avenue, Los Angeles, CA (jrhecht{at}mednet.ucla.edu).

Purpose. The results of clinical trials that led to modern first- and second-line chemotherapeutic regimens for metastatic colorectal cancer, including studies of recently introduced monoclonal antibody products that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), are described, as well as new therapeutic targets being studied and challenges in research to identify and evaluate new therapies. Summary. Modern chemotherapy regimens for first-line treatment of metastatic colorectal cancer contain fluorouracil, leucovorin, either oxaliplatin or irinotecan, and the VEGF inhibitor bevacizumab. The EGFR inhibitors cetuximab and panitumumab currently are reserved for second- or third-line therapy, but their role could change as the results of clinical research become available. The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin pathway, src kinases, and insulin-like growth factor-1 receptor are among the targets of current research. Identifying the subset of patients with metastatic colorectal cancer who stand to benefit from a particular therapy presents a challenge in conducting clinical research. Conclusion. Modern chemotherapeutic and monoclonal antibody regimens have improved survival in patients with meta-static colorectal cancer. The optimal combinations, timing, and sequence of agents remain to be determined. Index terms: Antibodies; Antineoplastic agents; Bevacizumab; Cetuximab; Colorectal neoplasms; Combined therapy; Fluorouracil; Irinotecan; Leucovorin; Neoplasms metastasis; Oxaliplatin; Panitumumab; Site of action

 

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. GIANNOPOULOU, A. ANTONACOPOULOU, P. MATSOUKA, and H. P. KALOFONOS Autophagy: Novel Action of Panitumumab in Colon Cancer Anticancer Res, December 1, 2009; 29(12): 5077 - 5082. [Abstract] [Full Text] [PDF]